Scriver R, Beaudet AL, Sly WS, Valle D, eds. New York: McGraw-Hill
Brusilow SW, Horwich AL (1995) Urea cycle enzymes. In Scriver R, Beaudet AL, Sly WS, Valle D, eds. The Molecular and Metabolic Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1187-1232.
Substrate induced conformational change in a trimeric ornithine transcarbamoylase
Ha, Y, McCann MT, Tuchman M, Allewell NM (1997) Substrate induced conformational change in a trimeric ornithine transcarbamoylase. Proc Natl Acad Sci USA 94: 9550-9555.
Crystal and molelcular structures of native and CTP ligated aspartate carbamoyltransferase from Esherichia coli
Honzatko RB, Crawford JL, Monaco HL, et al (1982) Crystal and molelcular structures of native and CTP ligated aspartate carbamoyltransferase from Esherichia coli. J Mol Biol 160: 219-263.
Characterization of point mutations in the same arginine codon in three unrelated patients with ornithine transcarbamylase deficiency
Maddalena A, Edward SJ, O'Brien WE, Nussbaum RL (1988) Characterization of point mutations in the same arginine codon in three unrelated patients with ornithine transcarbamylase deficiency. J Clin Invest 82: 1353-1358.
Expression, purification and kinetic characterization of wild type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonemia
Morizono H, Tuchman M, Rajagopal BS, et al (1997a) Expression, purification and kinetic characterization of wild type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonemia. Biochem J 322: 625-631.
Late onset ornithine transcarbamylase deficiency: Function of three purified recombinant mutant enzymes
Morizono H, Listrom CD, Rajagopal BS, et al (1997b) Late onset ornithine transcarbamylase deficiency: function of three purified recombinant mutant enzymes. Hum Mol Genet 6: 963-968.
Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes
Morsy MA, Zhao JZ, Ngo TT, et al (1996) Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes. J Clin Invest 97: 826-832.
